Loading patent…
AssigneeChildren's Medical Center Corporation
InventorsShawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Adonia E. Papathanassiu, William Fogler
Estimating the term…
The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.
A process for preparing 2-methyl-2-phthalimidinoglutaric acid comprising the steps of
A process for the separation of the (S) and (R) enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid comprising the steps of
A process for the separation of the (S) and (R) enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid comprising the steps of
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a stereoisomer of a compound having the formula
A method of inhibiting undesired angiogenesis in a human or animal comprising administering to the human or animal with undesired angiogenesis an angiogenesis inhibiting amount of a stereoisomer of a compound having the formula
A method of treating cancer in a human or animal comprising administering to the human or animal having cancer a cancer treatment effective amount of a stereoisomer of a compound having the formula
Dependencies are inferred from the claim text.